Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citicoline added to standard treatment for autism spectrum disorder
IRCT20231030059898N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of citicoline in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Finding a new drug to treat autism. Started Nov 2023; status: completed.
02
Drugs
citicoline
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT20231030059898N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231030059898N1.